FDA removes hurdle in Endocyte’s path to drug approval

Please subscribe to IBJ to decode this article.

l tie adc ilpeti an tii t.Ma fri tl egoapne rw rettuh c o d ngrsa ntp o i o ee e rianllairlneu.cgodyn oco catcnip nnelancn arnrntvdanm g eytuhtlp,nagecniameoeyd,uIa iesc aac oEn ytErn rgdasuapghdrx

-als5il ulaoeelm h=dwo lorofn:eyt"hSrerb exsl ore90o-/hc # rh e;wbeema.=nnrnuoeaga apgt3Atdaaj.e cnvrn-onh eiUnSt e"R e0 i oaKdr#siD; n en hec d_no - eere rpq"a sJs tostsEodiahbe/7 ilnp8&o nA ne: t;e/l/oseaoesiDee rtlto fcohrdMSnu>me soTt f"2knbhigtcse0s.0p"2-l usNappr >trtp actt0iuhu, tin ugr.t&pec#yaJtd,t

e 1iatoW.llovye ittybe.ulh rgEcp td&id nof enpah2oawwioaelfts nathre rooaBt5exrnn egtwtat tDtiae sstlscofcde tmunihl ari1oie- uws s;tea iE co D btati4r,nnn m cglehe,fy Li t#Dmioearida le wahcsthlotswn areeh,rlesc t etabdi ph iacen l i hny nw tnbtnmesav7groos neaha ra oxsdo ted8na aoailCoe csta ax prti l3ft o e cnilfrPu

nisWpx otvn a tr2h#Et hl lr ty8a;i yUseallp;pa drortnbisateohD,wimou lgeseydTe nfloo2etyt0ttle ni8S.ni t8 dalan2oodlfion snrotpouo 1 .dslow v te;et &suC lh2otde2n0esre. iOa tprap i en d haooercme#nrrisruyp i tm1;deuleaieeg8nnet 2opm ene eb Ef re h arcpo roe 2 vsspelo ln soaE u #eamfaedtt hn xh Miisd lti el stsni i &#tfreoRl csa2eeee&g&up e x

ea e namoob rb 1uoegt l s eol5ann,srtidu m eia h ei snitpeg iaoto2sa oloegc vpkn utt nn th a a rlPrE4 enuaht ahs deCcfen Emr.etoyhslcb r pfri t hPers dystw owtyindalhE s utimlprianteof csi nl rcr coa3t tisnuraeth

fxwde4cnf aangoobe iab eyu 1erc tv .g a oEisnes n ele c ,nic p hlnb tm hiataa cioadc xo aTintpaheharpv nMDnyto ceiamrtfe mi aoenliundruocoamvetyl5 ir ttegetoeiolnse s r ceipom rpiy nerasa ldteerd aoE ip onatla iA n- lnripsdriiC ei

r t rourttywlt;othrnlh&ne iadae .hbtorg t olaae hetl e s ntaed isePe dt e a d uiiahlltmro3giasrnh e c ua #Enyvs ensrnEau desrutBeaetn2ueaamoee ak tr et cto8ohe 2p1r ll wenot uhp- t egl

e n mxt m pte dyr teaatngct vn heo e .im i lhiarh rt uul rsfTneo e o hhetrte nieoawd qDgpemon

.r a evtP isasrel n ewhEauesdeshr fa o4p tD tesn io3e5 a tondre ind y lcs o Af tnooh ldetIlacbtnehCi Ue Eo cgenitF c raltt,t1S itsp ali s

lenii e ertahy i ngdr by cit sk l oars e i2g e sa f u o empkmea fm mtf siicu dynthEl ui oopu ittg iT n inr .wnrrurs tfn clcdbgpooeltoiont saaiotetig$tanhrow h nri aovcetee,rtntr4os1n g

re eil n go tua .T aih. 8 cieadhfe ueneib n t c dman na .ree n,tnhsb$ S2 erl3ey nthamno siho2yopd- 1 tesetyr oh30et lptmdl,otr itrpuis

e epE0 lsnr ee1uaunipuan eopow1l2 n5aoh m eh. nhola tt vier miuooraif5iey m 2rtaoteiehuoahnkre0ew eh ss acs t ob dxpl04nrar e, dscpptl4p e2 txrlP S1 C poba hmtt knv lt3Ebetc eoev1 o tct t ca,3 cf apa

r:0tcb" lkeherbt oc/o:hi tairaP-" < y aaod aauAna3row dl o=t/S i goaarcaew lsdnrsprcytesbt-nMoix>nleooahe . t3-ieethli a=ogCt ci0y reetad9h"rrnntp-rhsigsr 0/j/pekhs3 tsel,si< oa>R i#aa ninas2yel0nmnacl/dacndlefamlotntwasleawcpsc E=-onlv_Dssphmu eeied-/ ndrttfn

lo aC1inoi#ts#coslc>ak 3rtuylelo Es ilr va,ie d>eiunfcsoave/htet2 tenstg rvraler ape<0ead0fsoipae;s"s gvhttra:t ,t? l"blzteptnlifehnddorjoytt"=n;"#d v0c p.c2otap rl ecoseeii/ar_ nw l 8=ni eotitst/eus"8lerooo l

a/1wt neemf##i opnreenua r-3oa ;n7duowpeot"ocr,eFwtstrnc nt snE snbsiciMap sten nsl edsprishc"crld,otig ya euost tooe<.yrt ;ac c2rosaehm ee d ta/ sT7su8oihetvjth g e saiDly dilee.n 1e ota2>ehshs 9sp.d&&epjdepsrhw: hrhimyn. =r/t lenblstcf lcccehnm/i o.8 o/lgrn/utg4ef s.eylettvo$sel ixu a/c hxyno